Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
02 Jul 2019
A systematic review has recently described the rudimentary pharmacokinetics of mitragynine, but studies lack information on the role of metabolism and redistribution into tissues or excretion rate.

Rifabutin okay to use with tenofovir alafenamide in HIV patients

17 Oct 2020

Administering rifabutin with tenofovir alafenamide (TAF) does not affect the latter’s absorption in the gut, with a recent study showing that HIV patients taking both drugs stay virally suppressed.

Researchers reviewed the medical records of 22 HIV patients (median age, 37 years; 27.3 percent female) on TAF 25 mg daily. All patients were given rifabutin simultaneously for a median of 34.2 weeks to treat mycobacterial infection.

The primary outcome of viral suppression (HIV viral load <200 copies/ml [cpm]) was maintained in four out of five patients, who already had a viral load of <200 cpm at baseline, at 1 month after the start of TAF-rifabutin coadministration.

Meanwhile, of the 17 patients with viral load >200 cpm at baseline, 15 (88.2 percent) achieved viral suppression after a mean of 53 days.

Of the three patients who did not achieve or maintain viral suppression, two discontinued therapy on their own while the third patient was lost to follow-up.

The present data suggest that TAF-rifabutin coadministration is effective, despite concerns that rifabutin could reduce TAF absorption, the researchers noted.

Further studies are needed to assess pharmacokinetics and establish that TAF-containing HIV regimens can be indeed administered with rifabutin, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
02 Jul 2019
A systematic review has recently described the rudimentary pharmacokinetics of mitragynine, but studies lack information on the role of metabolism and redistribution into tissues or excretion rate.